REPL logo

Replimune Group Inc. (REPL)

$19.69

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on REPL

Market cap

$1.87B

EPS

-2.79

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.936859

Price on REPL

Previous close

$21.41

Today's open

$21.36

Day's range

$19.60 - $21.55

52 week range

$1.50 - $23.54

Profile about REPL

CEO

Sushil Patel

Employees

465

Headquarters

Woburn, MA

Exchange

Nasdaq Global Select

Shares outstanding

94800404

Issue type

Common Stock

REPL industries and sectors

Healthcare

Biotechnology & Life Sciences

News on REPL

Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet

The consensus price target hints at a 29.5% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • 42 minutes ago

news preview

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress

Replimune shares surge 80% as Tudriqev's commercial launch gains traction, earnings beat expectations and pipeline progress strengthens growth prospects.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying

Bears are crowding into a small group of stocks, and one name has nearly its entire float sold short.

news source

Benzinga • Nov 11, 2026

news preview

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade

The mean of analysts' price targets for Replimune Group (REPL) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Nov 2, 2026

news preview

Replimune: 3 Key Takeaways for Long-Term Investors

Replimune ended the second quarter with $307.8 million in cash. Over 15 institutions wrote prescriptions within 20 business days.

news source

The Motley Fool • Oct 29, 2026

news preview

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript

Replimune Group, Inc. ( REPL ) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Arleen Goldenberg Sushil Patel - CEO & Director Michelle DiNapoli - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Capital Markets Equity Research Allison Bratzel - Piper Sandler & Co., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Mubeen Mosaheb Romy O'Connor - Van Lanschot Kempen NV Presentation Operator Good day, and thank you for standing by. Welcome to the Replimune's Second Quarter Fiscal 2027 Earnings Conference Call.

news source

Seeking Alpha • Oct 28, 2026

news preview

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass.

news source

GlobeNewsWire • Oct 28, 2026

news preview

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.

news source

GlobeNewsWire • Oct 22, 2026

news preview

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026

news source

GlobeNewsWire • Oct 5, 2026

news preview

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70.

news source

GlobeNewsWire • Oct 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Replimune Group Inc.

Open an M1 investment account to buy and sell Replimune Group Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in REPL on M1